PT-141
Hormonal Approved · US Human trials
Also called Bremelanotide, Vyleesi
A ring-shaped peptide derived from Melanotan-2. It activates melanocortin receptors in the brain, mainly MC4R, and increases sexual desire through the nervous system rather than through blood flow. Nausea and brief rises in blood pressure are the main side effects.
Why people take it
What studies report
- Meaningful increase in sexual desire and satisfying events in phase 3 trials
- Works through the brain rather than blood flow, so it suits people PDE5 drugs do not
How it works
Acts centrally on melanocortin receptors in the brain rather than on blood flow, which is why it works where PDE5 drugs do not.
In practice Off-label
- Used situationally ahead of intimacy rather than on a schedule
- Users commonly reduce the amount to manage nausea, which is the main complaint
- Sometimes combined with PDE5 drugs, since it works on desire rather than blood flow
Reported real-world use, not evidence and not a recommendation.
Worth knowing: Approved for premenopausal women with HSDD. Nausea affects about 40%, and it transiently raises blood pressure.
Status: FDA-approved (Vyleesi, 2019) for low sexual desire in premenopausal women.
- Route
- Subcutaneous injection (the approved product is an auto-injector)
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Formula
- C50H68N14O10
- Molecular weight
- 1025.2 g/mol
- CAS
- 189691-06-3
- Available as
- 10 mg
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.